Dermatology · 2002 · 55 citations · 17 references
MedicineDermatologyPharmacotherapyImmunotherapyInflammationRheumatologyCytokine BiologyCytokine RegulationCytokine-based TherapyInflammatory DermatosesInflammatory Skin DiseasesPsoriatic ArthritisDrug-induced PsoriasisDurable Clinical ResponseImmunosuppressive CompoundsPsoriasis ImmunopathologyPsoriasis TherapyPsoriatic DiseaseSkin Erythema
We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition. Two weekly injections of 25 mg of the tumour necrosis factor alpha inhibitor etanercept led to a rapid improvement of his psoriatic arthritis, as well as regression of the pustular eruption, while residual erythema was still present. The clinical response was reflected by an increase in circulating interleukin (IL) 10 and a decrease in IL-6 and IL-8 serum levels during treatment. We conclude that etanercept may be a safe and effective therapy not only in severe psoriatic arthritis, but also in cases of pustular rebound after withdrawal of immunosuppressive agents.
17
Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst et al. · New England Journal of Medicine · 1999 · 2.1K citations · Full text
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Philip J. Mease, Bernard S. Goffe, James M. Metz et al. · The Lancet · 2000 · 1.5K citations
Etanercept Therapy in Rheumatoid Arthritis
Larry W. Moreland · Annals of Internal Medicine · 1999 · 1.4K citations
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.
B J Nickoloff, Gerald D. Karabin, Juliet N. Barker et al. · PubMed · 1991 · 435 citations
Medicine, Dermatology, Immunology +14